<DOC>
	<DOCNO>NCT01149200</DOCNO>
	<brief_summary>Study assess effectiveness TC-6499 treatment constipation predominant IBS patient 28-day period .</brief_summary>
	<brief_title>Proof-of-Principle Study TC-6499 Treatment Constipation Predominant Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>This randomize , double blind , placebo control study maximum 24 subject constipation predominant irritable bowel syndrome ( IBS-C ) . Sixteen subject receive active treatment 8 subject receive match placebo . There 21-day screening phase 1st study drug administration Day 1 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Men IBSC ( ROME III ) 18 65 year age , inclusive . Women IBSC ( ROME III ) 55 65 year age , 18 55 year age documentation nonchildbearing potential status ( surgical sterilization one year post last menses elevate FSH/LV ) . All subject body mass index ( BMI ) 18 34 kg/m2 , inclusive body weight less 45 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS-C</keyword>
</DOC>